Literature DB >> 3361668

Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.

R J Torrence1, L R Kavoussi, W J Catalona, T L Ratliff.   

Abstract

Several factors were evaluated for prognostic significance in 104 patients with a history of recurrent superficial bladder cancer treated with a 6-week course of intravesical bacillus Calmette-Guerin. Purified protein derivative skin test reactivity, tumor stage, tumor grade and number of previous tumor recurrences were evaluated in all patients. In addition, the prognostic value of a granulomatous response in the bladder was evaluated in 62 of the 104 patients. A significant correlation was reconfirmed between purified protein derivative reactivity and status free of tumor (p equals 0.041) after additional followup on 62 patients from a previous report. A significant correlation also was observed in the total patient population (p equals 0.054). Over-all, 60 per cent of the 62 patients and 52 per cent of the 104 patients whose purified protein derivative test converted from negative to positive remained free of tumor, compared to only 28 per cent of the 62 patients and 28 per cent of the 104 whose test failed to convert to positive. Mean followup was 29.3 +/- 5.7 months in the 62 patient subgroup and 23.5 +/- 5.8 months in the total 104 patients. Bladder granuloma data were available only for the 62 patient subgroup in the previous report. With extended followup, the significant correlation previously reported between status free of tumor and granulomatous response on bladder biopsy was lost. Over-all, 29 of 37 patients (51 per cent) with granulomas compared to 8 of 25 (32 per cent) without granulomas remained free of tumor (p equals 0.132). Tumor stage and grade, and number of previous tumor recurrences failed to show a significant correlation to status free of tumor. These results show that with extended followup, granulomatous response in the bladder lost its statistical correlation with status free of tumor, while a significant correlation was maintained for purified protein derivative responsiveness. This level of statistical significance was borderline and the purified protein derivative skin test response should not be considered useful as a prognostic indicator in individual patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361668     DOI: 10.1016/s0022-5347(17)42723-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.

Authors:  M D Melekos; A Pantazakos; S Markou; C Skopa; A Athanassopoulos; G Barbalias
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

2.  Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy.

Authors:  Masashi Matsushima; Eiji Kikuchi; Hirotaka Akita; Akira Miyajima; Mototsugu Oya; Masahiro Jinzaki
Journal:  Int J Clin Oncol       Date:  2017-02-10       Impact factor: 3.402

3.  Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.

Authors:  Niannian Ji; Neelam Mukherjee; Edwin E Morales; Maggie E Tomasini; Vincent Hurez; Tyler J Curiel; Getahun Abate; Dan F Hoft; Xiang-Ru Zhao; Jon Gelfond; Sourindra Maiti; Laurence J N Cooper; Robert S Svatek
Journal:  Oncoimmunology       Date:  2019-05-25       Impact factor: 8.110

4.  Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG.

Authors:  E Pieras-Ayala; J Palou-Redorta; J I Tomero-Ruiz; M Montlleó-González; J Salvador-Bayarri; J Vicente-Rodríguez
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

7.  Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin.

Authors:  J S Shin; J H Park; J D Kim; J M Lee; S J Kim
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

8.  Identification of polymorphisms and sequence variants in the human homologue of the mouse natural resistance-associated macrophage protein gene.

Authors:  J Liu; T M Fujiwara; N T Buu; F O Sánchez; M Cellier; A J Paradis; D Frappier; E Skamene; P Gros; K Morgan
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

9.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

Authors:  E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 10.  Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

Authors:  Timothy P Kresowik; Thomas S Griffith
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.